Kisqali (ribociclib) and Femara (letrozole) are two different cancer drugs often used together in certain breast cancers.
- Kisqali (ribociclib): a CDK4/6 inhibitor. It slows cancer cell growth by blocking certain proteins needed for cell division.
- Femara (letrozole): an aromatase inhibitor. It lowers estrogen levels, which can help slow the growth of estrogen-receptor–positive breast cancers.
Together:
- In postmenopausal women with hormone-receptor–positive, HER2-negative advanced/metastatic breast cancer, ribociclib plus letrozole is a common first-line treatment option.
- Dosing and scheduling are specific (taken in cycles) and must be followed exactly as prescribed by your oncologist.
Common things to know:
- Side effects can include low white blood cell counts, fatigue, nausea, liver enzyme changes, and, with ribociclib, possible QT interval prolongation. Letrozole can cause hot flashes, joint pain, bone thinning, and fatigue.
- Interactions: ribociclib is affected by strong CYP3A inhibitors or inducers (e.g., certain antifungals, antibiotics, anticonvulsants, or rifampin). Avoid grapefruit and grapefruit juice, as they can raise ribociclib levels.
- Pregnancy/breastfeeding: not for use if pregnant or breastfeeding. Use effective contraception if you or your partner may become pregnant.
- Monitoring: blood counts, liver function tests, and sometimes ECGs are monitored during treatment.
If you’re asking about how they work together for your situation, or have a specific question about side effects, dosing, or what to expect, tell me a bit more and I can tailor the information. Always follow your doctor’s advice and talk to them or your pharmacist about any concerns or potential drug interactions.